Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

The Food and Drug Administration (FDA) approved Zepbound in December 2024 for treating obstructive sleep apnea (OSA). Medicare Part D may cover Zepbound, but only when a doctor prescribes it for OSA.

U.S. pharmaceutical giant Eli Lilly (LLY) is lowering the cost of its blockbuster weight loss medication Zepbound in an effort to reach more ...

Many employers and insurers are scaling back coverage and Medicare doesn’t cover the drugs for obesity. Meantime, some big ...

Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...

Wave goodbye to the Part D "donut hole" and hello to a $2,000 cap on the amount you'll pay for medications. But other changes ...

United Health Group, the largest U.S. health insurer by enrollees, was under pressure after Sen. Chuck Grassley, chairman of the Senate Judiciary Committee, sent the conglomerate's chief executive, ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

The drugmaker could also explain how it plans to promote Zepbound to older Americans covered by Medicare, now that the U.S. government health program for people aged 65 and older or who have ...

Feb 5 (Reuters) - Eli Lilly (LLY.N), opens new tab investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug ...

The drugmaker could also explain how it plans to promote Zepbound to older Americans covered by Medicare, now that the U.S. government health program for people aged 65 and older or who have ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the ...